NCT00592046 - A Phase I Trial of ZIO-101 in Hematologic Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Acute LeukemiaChronic Myeloproliferative DiseaseChronic Lymphoproliferative DiseaseMultiple MyelomaLymphomaPoor-risk Myelodysplasia (MDS)

Interventions

DRUG

ZIO-101 (Darinaparsin)

ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.

Trial Locations (1)

Houston